⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iiib melanoma

Every month we try and update this database with for stage iiib melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaNCT00056134
Melanoma (Skin)
Dendritic cell ...
18 Years - 120 YearsUniversity Hospital Erlangen
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibNCT01519427
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
Akt inhibitor M...
selumetinib
laboratory biom...
18 Years - National Cancer Institute (NCI)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node BiopsyNCT00897481
Melanoma (Skin)
gene expression...
mutation analys...
diagnostic labo...
immunohistochem...
sentinel lymph ...
- National Cancer Institute (NCI)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node BiopsyNCT00897481
Melanoma (Skin)
gene expression...
mutation analys...
diagnostic labo...
immunohistochem...
sentinel lymph ...
- National Cancer Institute (NCI)
Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaNCT00003895
Recurrent Melan...
Stage IA Melano...
Stage IB Melano...
Stage IIA Melan...
Stage IIB Melan...
Stage IIC Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
HPV 16 E7:12-20
gp100:209-217(2...
laboratory biom...
17 Years - National Cancer Institute (NCI)
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaNCT00436605
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
dasatinib
18 Years - National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNCT00470470
Acral Lentigino...
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
imatinib mesyla...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaNCT00390338
Melanoma (Skin)
polarized dendr...
non-polarized d...
18 Years - University of Pittsburgh
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By SurgeryNCT01748747
Recurrent Melan...
Stage IIA Melan...
Stage IIB Melan...
Stage IIC Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
Montanide ISA 5...
MART-1 antigen
laboratory biom...
Gag:267-274 pep...
resiquimod
18 Years - Mayo Clinic
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticNCT02094872
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
cytology specim...
MEK 162 therapy...
therapeutic pro...
laboratory biom...
quality-of-life...
18 Years - Yale University
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable MelanomaNCT06190249
Stage IIIB Mela...
Stage IIIC Mela...
Stage IIID Mela...
LN-144
Cyclophosphamid...
Mesna
Fludarabine
Interleukin-2 (...
Pembrolizumab
18 Years - Case Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaNCT00390338
Melanoma (Skin)
polarized dendr...
non-polarized d...
18 Years - University of Pittsburgh
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticNCT02094872
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
cytology specim...
MEK 162 therapy...
therapeutic pro...
laboratory biom...
quality-of-life...
18 Years - Yale University
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsNCT02296112
Recurrent Melan...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
trametinib
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558NCT01176461
Melanoma (Skin)
MART-1
NY-ESO-1
gp100:209-217(2...
gp100:280-288(2...
Montanide ISA 5...
BMS-936558
16 Years - H. Lee Moffitt Cancer Center and Research Institute
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable MelanomaNCT06190249
Stage IIIB Mela...
Stage IIIC Mela...
Stage IIID Mela...
LN-144
Cyclophosphamid...
Mesna
Fludarabine
Interleukin-2 (...
Pembrolizumab
18 Years - Case Comprehensive Cancer Center
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryNCT01701037
Recurrent Melan...
Stage IIB Melan...
Stage IIC Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
dabrafenib
trametinib
laboratory biom...
18 Years - 90 YearsVanderbilt-Ingram Cancer Center
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegNCT00565968
Melanoma (Skin)
melphalan
sorafenib tosyl...
gene expression...
protein express...
western blottin...
pharmacological...
18 Years - Duke University
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic MelanomaNCT00715793
Malignant Melan...
Decitabine
Temozolomide
biopsy
18 Years - University of Pittsburgh
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node BiopsyNCT00897481
Melanoma (Skin)
gene expression...
mutation analys...
diagnostic labo...
immunohistochem...
sentinel lymph ...
- National Cancer Institute (NCI)
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryNCT02203604
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
aldesleukin
ipilimumab
laboratory biom...
18 Years - Rutgers, The State University of New Jersey
Study of Families With MelanomaNCT00445783
Melanoma (Skin)
gene expression...
mutation analys...
immunohistochem...
laboratory biom...
examination
mutation carrie...
study of high r...
18 Years - National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNCT00470470
Acral Lentigino...
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
imatinib mesyla...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaNCT00390338
Melanoma (Skin)
polarized dendr...
non-polarized d...
18 Years - University of Pittsburgh
Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaNCT00003895
Recurrent Melan...
Stage IA Melano...
Stage IB Melano...
Stage IIA Melan...
Stage IIB Melan...
Stage IIC Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
HPV 16 E7:12-20
gp100:209-217(2...
laboratory biom...
17 Years - National Cancer Institute (NCI)
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary MelanomaNCT00450593
Hereditary Mult...
Melanoma (Skin)
gene expression...
microarray anal...
molecular genet...
mutation analys...
laboratory biom...
mutation carrie...
study of high r...
- National Cancer Institute (NCI)
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaNCT00436605
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
dasatinib
18 Years - National Cancer Institute (NCI)
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryNCT02203604
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
aldesleukin
ipilimumab
laboratory biom...
18 Years - Rutgers, The State University of New Jersey
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaNCT00492505
Melanoma (Skin)
cisplatin
sorafenib tosyl...
tamoxifen citra...
adjuvant therap...
18 Years - National Cancer Institute (NCI)
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticNCT02094872
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
cytology specim...
MEK 162 therapy...
therapeutic pro...
laboratory biom...
quality-of-life...
18 Years - Yale University
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or SarcomaNCT02507076
Basal Cell Carc...
Eccrine Carcino...
Recurrent Adult...
Recurrent Melan...
Recurrent Skin ...
Squamous Cell C...
Stage III Adult...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Adult ...
Stage IV Melano...
isolated limb p...
melphalan
quality-of-life...
18 Years - Albert Einstein College of Medicine
Biomarkers to Predict Response to Interferon Therapy in Patients With MelanomaNCT00897546
Melanoma (Skin)
laboratory biom...
18 Years - 120 YearsEastern Cooperative Oncology Group
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryNCT01835184
Recurrent Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
Unspecified Adu...
cabozantinib-s-...
vemurafenib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: